BFRI

Biofrontera Inc. (NASDAQ:BFRI) is a specialized biopharmaceutical company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in October 2021 and focuses on commercializing dermatological treatments in the United States market. Biofrontera operates as the U.S. subsidiary of German-based Biofrontera AG, specializing in photodynamic therapy solutions for various skin conditions. The company has established itself as a significant player in the dermatology space, particularly in the treatment of precancerous skin lesions and other dermatological conditions.